Recent News

Metastatic RCC:

Tumor Progression Delayed with Angiogenesis Inhibitor Pazopanib

Posted: September 21, 2009

Inhibitor pazopanib significantly reduced the risk of progression in patients with advanced renal cell carcinoma. View the Article here Metastatic RCC-Tumor Progression Delayed with Angiogenesis Inhibitor Pazopanib

<< Archives Next Post >>

NICHOLAS J. VOGELZANG, M.D
Chair and Medical Director
Developmental Therapeutics and
Co-Chair GU Committee
US Oncology Research
c/o Comprehensive Cancer Centers of NV

3730 S. Eastern Ave.
Las Vegas, NV 89169

888.680.6376
nvogelzang@mdmeso.com